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Background: Korean red ginseng (KRG) is a processed ginseng from raw ginseng to enhance safety, preservation
and efficacy, known having beneficial effects on women’s health due to its estrogen like function. While estrogen
supplementation showed some modulation of endocrine disrupting chemicals, bisphenol A (BPA) has been focused
as a potential endocrine disrupting chemical. In this study, we examined the efficacy and safety outcomes of KRG
against BPA, focusing on female quality of life (QOL). Individual variations in susceptibility to KRG were also
investigated with the Sasang Typology, the personalized medicine used for hundred years in Korea.
Methods: We performed a single-blind randomized clinical trial. Study subjects were young women (N = 22),
consumed 2.7 g of KRG or placebo per day for 2 weeks and filled up questionnaires regarding gynecologic
complaints at the 4 time spots. We analyzed urinary total BPA and malondialdehyde (MDA), an oxidative stress
biomarker, with GC/MS and HPLC/UVD respectively, and diagnosed their Sasang Typology with the questionnaire
for the Sasang constitution Classification (QSCC II).
Results: KRG consumption decreased urinary BPA and MDA levels (ps < 0.05) and alleviated ‘menstrual irregularity’,
‘menstrual pain’, and ‘constipation’ (ps < 0.05). SoEum type (Lesser Yin person) among the Sasang types showed
significant alleviation in insomnia, flushing, perspiration and appetite by KRG consumption, rather than other Sasang
types. During the intervention, no one experienced any aggravated side effects.
Conclusion: We suggest KRG is efficient for protection for female QOL and BPA- exposure and – related oxidative
stress. However, individual variation in susceptibility to KRG should be further considered for identifying ideal therapy.
Trial registration: KCT0000920.
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Ginseng (Panax Ginseng Meyer) is one of the highest
selling herbal supplements in the world. The products of
Korean red ginseng (KRG) have been sold over half
of functional foods in Korea [1]. It costs approximately
600 million dollars in 2010. KRG has been traditionally* Correspondence: myang@sm.ac.kr
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unless otherwise stated.obtained through a steaming process from raw ginseng to
enhance safety, preservation and efficacy [2]. In the course
of the steaming process, ginseng starch is gelatinized, caus-
ing an increase in saponin content [3] (Table 1). In addition,
various functions of KRG have been reported, e.g. anti-
inflammatory, −coagulating, and -oxidative actions, en-
hancement of sexual function, and vasodilation [4-8].
Moreover, some researchers predicted beneficial effects
on KRG on women’s health, e.g. targeting postme-
nopausal symptoms, due to its estrogen like function
[9,10].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Comparison of ginsenoside contents (%) between
Korean white and red ginseng3
Ginseng Rg1 Re Rf Rh1 Rg2 Rb1 Rc Rb2 Rd Rg3
White 0.537 1.34 0.31 0.00 0.11 1.81 1.51 2.14 0.41 0.04
Red 0.492 1.11 0.24 0.12 0.13 1.96 1.47 2.17 0.72 0.12
Bold, higher in KRG than raw ginseng.
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endocrine disrupting organochlorine, 3,3′,4,4′,5-penta-
chlorobiphenyl (PCB126) in rat bone and uterus [11].
Ginseng improved the survival rate and sperm quality in
the guinea pigs exposed to 2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD), a notorious endocrine disrupting chem-
ical (EDC) [12]. In addition, KRG extract activated both
estrogen receptor (ER)α and ERβ and modulated the
mRNA levels of estrogen-responsive genes, such as pS2
and ESR1 in vitro study, e.g. MCF-7 cells, however, estro-
genic activity of KRG was not manifested in vivo study
such as female Sprague–Dawley rats [13]. In human
(women), KRG showed improvements in the Kupperman
index and in the menopause rating scale scores [14].
Taken together, we can suspect effects of KRG on fe-
male reproduction or gynecological complaints viaFigure 1 Characteristics of the Sasang (四象, four types) constitutionsphytoestrogenic structures or characteristics of triter-
penoid saponins in KRG.
However, ginsengs, usually white (raw) ginsengs, are
stimulants and may cause nervousness or sleeplessness.
There were some reports for their side effects, e.g. high
blood pressure, insomnia, restlessness, anxiety, euphoria,
diarrhea, vomiting, headache, nosebleed, breast pain or
vaginal bleeding [15]. On the other hand, processed gin-
seng, i.e. KRG, have been broadly used with less toxicity
after the process from raw ginseng. To avoid side effects
of ginseng, ‘the Sasang (四象, four Typology or Constitu-
tion)’, which explains the individual differences in behav-
ioral patterns, physical characteristics and susceptibility
to a certain disease and medicinal herb based on their
bio-psychological traits, has strongly recommended gin-
seng for Soeumin (少陰人, SE type) among the four
types [16,17].
The Sasang medicine was systematically theorized by
Jae-Ma Lee in his book ‘Dong-Yi-Soo-Se-Bo-Won (東醫
壽世保元)’ [The Principle of Life Preservation in Orien-
tal Medicine] published in the end of 19 century [16]. It
shows temperament-based guideline for safe and effect-
ive use of medical herbs including ginseng, ginger,
mahuang (Ephedra Sinica) and aconite, the latter two.
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used by traditional Korean medicinal doctors clinically
for over a century in Korea [18]. The four Sasang consti-
tutions, Taeyangin (太陽人, TY type), Soyangin (少陽人,
SY type), Taeeumin (太陰人, TE type), and Soeumin (少
陰人, SE type), were distinguished according to individuals’
(1) sensitivity to certain groups of herbs and medicines, (2)
equilibrium among internal organ functions, (3) physical
features and (4) psychological characteristics [19] (Figure 1).
On the other hand, EDCs have been received attention
among scholars and publics, because of their toxicities
threatening fertility, intelligence and survival [20]. Among
various EDCs, bisphenol A [2,2-bis(4-hydroxyphenyl)pro-
pane, BPA] has been focused as a potential EDC due to
broad uses of BPA products, e.g. plastic bottles, con-
tainers, tooth sealing, etc. Therefore, people can be easily
exposed to BPA in daily life. However, health risks of BPA
are not clearly determined, yet. Metabolites of BPA, such
as quinone- or semiqunone-compounds, are suspected as
toxic materials to induce reactive oxygen species (ROS)
[21]. ROS showed pathological roles in the female repro-
ductive tract [22]. BPA was detected in the urine of the
majority of women undergoing in vitro fertilization, and
was inversely associated with number of oocytes retrieved
and peak oestradiol levels [23]. We reported that BPA in-
duces oxidative biomarkers, malondialdehyde (MDA) and
8-hydroxydeoxyguanosine [24]. Therefore, BPA itself or its
induced ROS can be risky for female reproductive organs.
In this study, we investigated the chemopreventive ef-
fects of KRG against BPA and individual variations in
susceptibility to KRG regarding female quality of life
(QOL) to improve and to extend the application of
KRG. The Sasang Typology was used for individual vari-
ation for susceptibility to the KRG.
Methods
Materials
BPA, BPA-d16 and β-glucuronidase were purchased from
Sigma Chemical Co. (St. Louis, MO). Methyltertialrybuty-
lether (MTBE) was purchased from Burdick & JacksonFigure 2 The HPLC profile of KRG-capsule shows 10 major ginsenosid
folds; ginsenoside Rg1+ Rb1 = 6.87 mg/g).(Muskegon, MI). N,O-Bis (trimethylsilyl) trifluoroaceta-
mide (BSTFA) and trimethylchloro-silane (TMCS) were
purchased from Supelco (Bellefonate, PA). KRG and pla-
cebo capsules were kindly provided by the Korean Ginseng
Corp (Daejeon, S. Korea). These KRG capsules contained
300 mg of 6-year old KRG. Following quality control
guidelines of Korean FDA [25], we obtained quality guaran-
teed KRG capsules with identified 10 ginsenosides including
Rb1 and Rg1 from the Korean Ginseng Corp (Figure 2).
Placebo capsules did not contain KRG but contained the
same quantity of free-dried corn starch powder with the
KRG capsules, i.e. 238.13 mg of corn starch, 10 mg of
powder flavor of KRG and 1.88 mg of coloring matters.
Clinical trial
This trial was designed as a single-blind randomized
study, which was approved by Institutional Review Board
of the Sookmyung Women’s university (SM-IRB-10-0720-
004: Seoul, S. Korea). Inclusion criteria for the present
study are healthy young women (21–30 yrs), however,
who experienced pre-menstrual syndrome, e.g. menstrual
pain, menstrual irregularity, etc. We excluded the people,
who had any other health problems or took medicine. All
participants filled out the informed consents before par-
ticipating in this study. Volunteers who experienced men-
strual pain or irregularity were recruited on bulletins in
the above school. The consumption of KRG or placebo
was determined by lot, a simple random sampling. Con-
sidering safety and other previous clinical trials [26,27], we
administered 9 capsules of placebo or KRG (2.7 g of KRG
powder)/day to the subjects after meals for 2 weeks (N =
22: N = 11 for KRG; N = 11 for placebo). During the trial
period, we collected their urine before breakfast on 4
spots, day 0, 4, 8 and 14 days and stored at −20°C until
analysis was performed. At the same time, all subjects re-
corded daily food intake (items and volume/meal) during
the trial and filled out questionnaires containing items of
QOL, side effects of raw ginseng and potential endpoints
of EDCs including the 17 complaints, i.e. menstrual pain,
menstrual irregularity, cold hands and feet, anemia,es with detection time (KRG powder, 1.0037 g; dilution 19.93
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constipation, face flushing, dipsosis, headache, palpitation,
perspiration, nose -bleeding, and allergy, before the trial
and after the next menstruation. These complaints were
measured on 5-rating scales (1 to 5, severity increased
with the rate, i.e. 1 = not at all; 5 = severely affected].
We asked the subjects whether they consumed KRG or
placebo by daily phone calls and followed them up to
3 weeks after the trial.
In addition, we diagnosed all of the subjects into the
four types of the Sasang constitution with the question-
naire for the Sasang constitution classification (QSCC) II
made by the Sasang Medical Society of Korean Oriental
Medical Society [28]. Reliability of the QSCC II was con-
firmed by diagnoses of Dr. Hwang M-W, an expert of
the Sasang medicine. Based on our previous pharmaco-
kinetic study among female subjects (N = 21) for 2 weeks
regarding the intervention of KRG [2], we designed the
present study with over 20 subjects.
The participants were compensated not for the benefit
but for time spent and inconvenience associated with
participation in research activities. The IRB approved
the appropriateness of compensation.
Analysis of urinary BPA
We analyzed urinary BPA with GC/MS, following Kim
et al. method [29] with minor modification. In brief, the in-
ternal standard, BPA-d16, was added to 2 ml of each urine
sample and 1 ml of 0.2 M sodium acetate buffer (pH 5.2)
and 50 μL of 0.1% β-glucuronidase were added to the above
urine samples. After adding 1 ml of 5% K2CO3 (pH 7), we
incubated the reaction mixture at 55°C for 3 hrs and per-
formed twice of liquid-liquid extraction with 2.5 ml of
MTBE to collected supernatant after centrifuge. For deriva-
tization, 50 μl BSTFA/TMCS (99:1 v/v) was added to the
sample and the mixture was incubated in 60°C for 30 min.
We applied 1 μl of the derivatized sample to GC/MS:
Agilent 7890 plus gas chromatograph with a DB-5 ms (SW
54 bonded phase) capillary column (30 m × 0.25 mm I.D.,
0.25 μm film thickness), interfaced to an Agilent 5975C
mass selective detector (70 eV, electron impact mode). One
μl of the each sample was injected in split ratio of 5:1. The
flow rate was 9 ml/min. Helium was used as a carrier gas
for 1.0 ml/min and the temperature of injector was 280°C.
The oven temperature was initially 120°C for 1 min, raised
to 320°C at 20°C/min, and held for 2 min. Selected Ion
Monitoring (SIM) was performed for quantification of BPA
at m/z 357 and internal standard BPA-d16 at m/z 368.
Analysis of urinary MDA
We analyzed urinary MDA as an oxidative stress bio-
marker by its adducts with 2-thiobarbituric acid (TBA,
CAS number: 504-17-6) as a previously described method
[24] with minor modifications. Briefly, 300 μl of 0.5 M ofphosphoric acid was mixed with 50 μl of urine or 1,1,3,3,-
tetraethoxypropane (CAS number: 122-31-6) standards
and 150 μl of TBA reagent. The mixtures were heated at
100°C for 1 h. The tubes were chilled on ice for 5 min.
Five hundred μl of methanol was added to the mixtures,
and the mixtures were centrifuged at 13,000 × g for 10 min.
The supernatant fractions were transferred to glass auto-
sampler vials and 20 μl of each supernatant was analyzed
by HPLC. The levels of TBA-MDA adduct were deter-
mined at 532 nm on an isocratic HPLC system: The TSK
gel column ODS-80TM (5 μm, 4.6 mm × 150 mm, Tosoh,
Tokyo, Japan) was eluted with 50 mol/l potassium phos-
phate buffer (pH 6.8) and methanol (58:42, v/v). The flow
rate of mobile phase was 0.6 ml/min.
The HPLC system was composed of dual Younglin
SP930D pumps (Younglin, Seoul, Korea), MIDAS COOL
autosampler (Spark Holland, Emmen, Netherlands) and
SPD-10A UV–VIS detector (Shimadzu, Kyoto, Japan).
Statistical analyses
To confirm no differences between KRG and placebo
groups before the trial, we analyzed characteristics of sub-
jects with t-test or Fisher exact test. Shapiro-Wilk W test
was used to study the degree of normal distribution of
BPA levels and the 17 pharmacodynamic parameters in-
cluding menstrual pain, constipation, insomnia, etc. Re-
gression analysis was used to study association between
the KRG treatment and urinary BPA or MDA levels. Ef-
fects of KRG or BPA on the pharmacodynamics parame-
ters were analyzed with t-test or Wilcoxon test due to the
normality of the parameters. ANOVA (Analysis of vari-
ance) or Kruskal-Wallis test were also used to study effects
of the Sasang Typology on responses to KRG.
All statistical analyses were performed with JMP (Version
4, SAS institute, Cary, NC). Statistical significance was de-
fined as p < 0.05.
Results
Characteristics of subjects
All of the subjects were non-smoking women, and most
of them experienced menstrual irregularity or menstrual
pain [≥3 of the scale for disturbance in daily life (1 to 5),
1 = not at all; 5 = severely affected]. There were no
significant differences in the characteristics of subjects
between the KRG and placebo groups before the inter-
vention (Table 2). In addition, there were no differences
in the degree of the 17 symptoms between the two
groups (ps > 0.05). Thus, we confirmed the confidence of
the randomization in subjects for the intervention.
Lack of association between BPA exposure and
gynecologic complaints
We analyzed levels of total BPA (free or conjugated BPA
with phase II enzymes) in urine samples and used them
Table 2 Characteristics of subjects before the trial
General (mean ± std)a KRG (N = 11) Placebo (N = 11) p
Age (years) 22.91 ± 1.81 22.73 ± 1.68 0.81
BMI (kg/m2) 20.12 ± 1.69 20.83 ± 2.24 0.42
Urinary total BPA (ng/L) 3.17 ± 2.28 2.38 ± 1.98 0.41
Diet [N(%)]b
Instant food intakec 1.00
High 1 (9) 0 (0)
Moderate 4 (36) 4 (36)
Low 6 (55) 7 (64)
Diet balanced 1.00
Prefer meat 3 (27) 2 (18)
Balanced 8 (73) 9 (82)
Prefer vegetable 0 (0) 0 (0)
Sasang [N(%)]b
SYe 4 (36) 5 (45) 1.00
SE 3 (27) 2 (18)
TE 4 (36) 4 (36)
aT-test; bFisher exact test (2-tail).
cDegree of instant food-intake was classified with frequency: high, >10 times/
week; moderate, 5–10 times/week; low, <5 times/week).
dFrequency (times) of meat or fish consumption/week, ≥10 times, prefer meat;
3–9 times, balanced; ≤2, prefer vegetable.
eSoyangin (少陽人, SY type); Soeumin (少陰人, SE type); Taeeumin (太陰人,
TE type).
Figure 4 KRG decreased urinary BPA levels: KRG group, r = −0.16,
p < 0.01; placebo group, r = −0.06, p = 0.17 by regression analysis.
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were detected in 69% of the subjects during the trial.
‘BPA non-detectable’ samples were assigned 0.25 ng/L,
half of the limit of quantification (LOQ = 0.5 ng/L) of
analyzed BPA levels. The range of urinary total BPA was
0.25 ~ 7.60 (median 0.94) ng/L (Figure 3).Figure 3 Distribution of urinary BPA levels (ng/L): Histogram of
urinary BPA levels: X and Y axes show levels of BPA (ng/L) and
probability of all samples (N = 88 from 4 spots of 22 study
subjects), respectively. Upper part of figure shows an outlier box
plot with the square in the box showing the interquartile range.In addition, we analyzed associations between urinary total
BPA levels before the trial, i.e. the 0 day-levels, and the 17
complaints, which might influence QOL in females and has
been suspected as end points of EDCs. As results, we could
not find any association between urinary total BPA levels
and any complaint or the sum of complaints (ps > 0.05).Interaction between BPA and KRG
The KRG treatment significantly decreased urinary BPA
levels during the trial; however, the placebo did not
(Figure 4). This trend was shown from the 4th day of
the KRG treatment [levels of urinary BPA ‘before KRG
treatment’ vs. ‘at the 4th day of the KRG’ intake: mean ± std,
3.16 ± 2.28 ug/L vs. 1.38 ± 1.14 ug/L: p = 0.03 by Wilcoxon
test). Thus, effects of the KRG on urinary BPA levels
could even be detected in 4 days after initiation of the
KRG consumption.
As food can be the main exposure source of BPA [24],
we let the subjects have their usual diet style and keep
the same levels of BPA exposure during the intervention.
Therefore, we could not find any significant change in
urinary BPA levels in the placebo subjects during the
intervention. Thus, the above inverse relationship be-
tween the KRG treatment and urinary BPA levels reflects
that KRG protects from environmental BPA exposure
via inhibition of its absorption. We also analyzed associ-
ation between ‘KRG-reduced urinary BPA levels’ and ‘al-
leviation of the 17 complaints’ during the 2 weeks-trial.
However, we could not find any significant association
between them (ps > 0.05).Effects of KRG on urinary MDA
The range of urinary MDA levels was 0.37-6.7 uM (me-
dian, 2.34 uM). At first, we studied whether BPA induced
urinary MDA or not and found positive association
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0.10, p < 0.01). Therefore, we confirmed BPA induced
urinary MDA in the present subjects.
Secondly, we investigated effects of KRG on BPA-
induced MDA and found reduced urinary MDA levels
not in the control (slope = −0.02, R2 = 0.01, p = 0.62) but
in the KRG group (slope = −0.09, R2 = 0.11, p = 0.04).
Therefore, we can estimate KRG has desirable effects on
BPA-related oxidative stress.
Effects of KRG on the 17 complaints
We studied effects of KRG on the 17 complaints. As re-
sults, we found that the KRG treatment significantly al-
leviated ‘menstrual irregularity’, ‘menstrual pain’, and
‘constipation’, although the above significances were not
confirmed by the relative comparison with placebo
(Figure 5).
In addition, there was no one who quit the trial due to
side effects of KRG and no one experienced side effects
of raw ginseng, e.g. insomnia, diarrhea, headache, nose-
bleed, breast pain, etc., in the present study. Therefore,
KRG has a potential to be safe and chemopreventive for
the above complaints.
Effects of the Sasang constitutions on the KRG efficacy
We diagnosed the Sasang constitutions of the subjects with
the QSCC II. As a result, there were three kinds of consti-
tutions in the present subjects: SY (N= 9), SE (N= 5) andFigure 5 KRG lowered women’s gynecological and QOL-related compTE (N = 8). Considering the Sasang constitutions, we ana-
lyzed effects of KRG on the 17 complaints. As results, sus-
ceptibility to KRG-induced alleviation of perspiration,
anemia and flushing were different due to the Sasang con-
stitutions (Figure 6): Particularly, the SE type showed sensi-
tive responses to KRG, compared to other types. When we
analyzed the differences of the KRG effects on the above
three complains between two groups (SY vs. SE; SE vs. TE;
SY vs. TE), we found borderline significant alleviation of all
of the complains in the SE type, compared to that in the
SY type (0.05 < ps < 0.1). However, there were no differ-
ences of the KRG effects between the SE and TE types and
between the SY and TE types.
After regrouping the subjects into two groups, i.e. the
SE type and the other (SY and TE) type, we observed ap-
petite and insomnia in the 17 complains were signifi-
cantly reduced by the KRG in the SE type, compared to
the other types (ps < 0.05).
When we compared effects of KRG on all complains
to those of placebo in the same Sasang type, we found
insomnia in the SE type and headache and menstrual
pain in the TE type were significantly reduced by the
KRG consumption (ps < 0.05).
Discussion
EDCs are toxic chemicals to target reproductive organs
and induce infertility [30-32]. Titus-Ernstoff et al. provided
evidence of menstrual irregularity and delayed menstruallaints: *<0.05; astudent t-test; bWilcoxon test.
Figure 6 The Sasang Constitutions showed different responses to KRG (N = 4, 3, and 4 for SY, SE and TE, respectively, in the
KRG-treated group): A. The Sasang Constitutions showed significantly different responses in KRG-induced alleviation of perspiration: p = 0.04
by ANOVA); B. The Sasang Constitutions showed significantly different responses in KRG-induced alleviation of flushing (p = 0.03 by Kruskal-Wallis
test); C. The Sasang Constitutions showed significantly different responses in KRG-induced alleviation of anemia (p = 0.04 by Kruskal-Wallis test).
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ethylstilbestrol in utero [33]. Menstrual irregularity and
pain among the studied 17 complaints are well known
complaints, which influence QOL in females and are asso-
ciated with various female reproduction diseases [34,35].
BPA has been suspected to disrupt female reproduction
systems: For example, levels of BPA in blood are associ-
ated with a variety of conditions in women including
endometrial hyperplasia, recurrent miscarriages, sterility,
and polycystic ovary syndrome [31]. However, some diet,
such as folic acid, soy products, etc., can modify end
points of BPA via epigenetic modulation [36]. There-
fore, we studied effects of BPA on female reproductive
complaints, however, could not find any association be-
tween exposure levels of BPA and female symptoms. Thus,
current BPA exposure levels in the present study may not
affect female complaints. In addition, simultaneous expos-
ure of chemopreventive materials with BPA in real envir-
onment is suspected to alleviate BPA toxicity.
Secondly, we focused on effects of KRG on BPA expos-
ure and found KRG lowered urinary BPA levels (Figure 4)
and BPA-related urinary MDA levels (Figure 5). We previ-
ously reported that the wheat sprout (Triticum aestivum)
juice, whose main component is chlorophyll, decreases
urinary BPA levels and reduces BPA-related oxidative
stress [24]. The basic structure of chlorophyll is a porphy-
rin ring and the chemopreventive mechanism of porphy-
rins is suspected as trapping reactive forms of xenobioticsby nucleophilic attack [37]. As like as porphyrins, the gin-
senosides of triterpen saponins in KRG can attach to aro-
matic rings with hydroxyl groups and create an electron
rich environment that traps the ROS. Thus, our study sug-
gests KRG inhibits BPA absorption and BPA- related oxi-
dative stress.
Thirdly, people can suspect effects of KRG on menstrual
irregularity and pain or other female-related complaints,
considering phytoestrogenic structures of the ginsenosides
in KRG. A case report even showed menometrorrhagia
and tachyarrhythmia as side effects of ginseng [38].
However, our present results indicated KRG did not
have any female-related side effects, but actually
alleviated ‘menstrual irregularity’, ‘menstrual pain’, and
‘constipation’ (Figure 6). Regarding constipation in par-
ticular, a recent Japanese study showed that a ginseng-
included oriental medicine, consisting of three crude
drugs [processed ginger, ginseng and zanthoxylum fruit
(5:3:2)], improved stool frequency and alleviated bloating
and abdominal pain in patients with chronic constipation
[39]. In addition, KRG improved fatigue, insomnia and de-
pression in postmenopausal women by a decrease in
cortisol/dehydroepiandrosterone sulphate ratio [40]. A
recent report also showed KRG improved the quality of
sleep [41]. Taken together, KRG seems to be beneficial
for female-related QOL.
However, individual variation in susceptibility to KRG
should be tested. Therefore, we focused on the Sasang
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QOL outcomes of KRG. In the present study, effects of
KRG on anemia, flushing, and perspiration were affected
by the Sasang constitutions (Figure 6). That is, the SE
types showed high efficacy of KRG compared to others.
These results support the recommendation that ginseng is
a proper medicine for the SE type [15,18]. Moreover, there
was no one who quit the trial due to side effects of KRG
or no one experienced aggravated side effects of raw gin-
seng, e.g. insomnia, diarrhea, headache, nosebleed, breast
pain, etc., in the present study. Therefore, side effects of
raw ginseng, which were observed out of Korea [42], can
be related to ginseng misuse regardless consumers’ indi-
vidual variations. Taken together, KRG, the processed gin-
seng, can be broadly used for not only the SE type but also
other types with less toxicity than raw ginseng.
Finally, our study includes some of study limitations. At
first, some of our results were based on questionnaires,
useful epidemiological tools, for end points of female
symptoms. The subjects filled out the degrees of the symp-
toms on the questionnaires for four times during the trial.
Therefore, our results should be supported by future phar-
macodynamic data, e.g. blood levels of various biochemical
parameters. In addition, we have a general limitation of
human study, i.e. control of subjects. Although we did our
best to control food-related confounders, we could not
completely control all factors of food consumption. There-
fore, KRG-interacted food should be clarified and consid-
ered for future study. Thirdly, we decided the period of
trial as 2 weeks for sub-acute tests, considering short half-
life of BPA of 12 hrs. In addition, the limited number of
subjects and the outliers in the present study might induce
relatively broad variation of KRG effects (Figure 4). More-
over, all humans cannot be categorized into 4 groups of
the Sasang constitutions. Therefore, future longer and lar-
ger scaled trials than the present period are desired to con-
firm our findings.Conclusion
In conclusion, the present trial showed that KRG lowers
urinary BPA levels and BPA-induced MDA levels and al-
leviates gynecological complaints without side effects of
raw-ginseng. Therefore, KRG is thought to be relatively
safe and chemopreventive from BPA-or female-related
diseases.
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